Rasagiline
Identifieur interne : 001435 ( Main/Exploration ); précédent : 001434; suivant : 001436Rasagiline
Auteurs : Anthony Schapira [Royaume-Uni] ; Guy Bate [Royaume-Uni] ; Peter KirkpatrickSource :
- Nature Reviews Drug Discovery [ 1474-1776 ] ; 2005-08.
Abstract
Rasagiline (Azilect; Lundbeck/Teva Pharmaceutical Industries) was given marketing approval by the EMEA for the treatment of Parkinson's disease in February 2005. It is the first in a new generation of selective monoamine oxidase inhibitors, and acts to alleviate the dopaminergic deficit characteristic of the disease.
Url:
DOI: 10.1038/nrd1803
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rasagiline</title>
<author><name sortKey="Schapira, Anthony" sort="Schapira, Anthony" uniqKey="Schapira A" first="Anthony" last="Schapira">Anthony Schapira</name>
</author>
<author><name sortKey="Bate, Guy" sort="Bate, Guy" uniqKey="Bate G" first="Guy" last="Bate">Guy Bate</name>
</author>
<author><name sortKey="Kirkpatrick, Peter" sort="Kirkpatrick, Peter" uniqKey="Kirkpatrick P" first="Peter" last="Kirkpatrick">Peter Kirkpatrick</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:C53EDBB7F673A33C12D33AC9B93DBB5D5F1B2FF3</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1038/nrd1803</idno>
<idno type="url">https://api.istex.fr/document/C53EDBB7F673A33C12D33AC9B93DBB5D5F1B2FF3/fulltext/pdf</idno>
<idno type="wicri:Area/Main/Corpus">001050</idno>
<idno type="wicri:Area/Main/Curation">000E60</idno>
<idno type="wicri:Area/Main/Exploration">001435</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Rasagiline</title>
<author><name sortKey="Schapira, Anthony" sort="Schapira, Anthony" uniqKey="Schapira A" first="Anthony" last="Schapira">Anthony Schapira</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Clinical Neurosciences, Royal Free and University College Medical School, London, NW3 2PF</wicri:regionArea>
<wicri:noRegion>NW3 2PF</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Bate, Guy" sort="Bate, Guy" uniqKey="Bate G" first="Guy" last="Bate">Guy Bate</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>IMS Health, 7 Harewood Avenue, London, NW1 6JB</wicri:regionArea>
<wicri:noRegion>NW1 6JB</wicri:noRegion>
</affiliation>
<affiliation><wicri:noCountry code="no comma">E-mail: gbate@uk.imshealth.com</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Kirkpatrick, Peter" sort="Kirkpatrick, Peter" uniqKey="Kirkpatrick P" first="Peter" last="Kirkpatrick">Peter Kirkpatrick</name>
<affiliation><wicri:noCountry code="syntax">???</wicri:noCountry>
</affiliation>
<affiliation><wicri:noCountry code="no comma">E-mail: p.kirkpatrick@nature.com</wicri:noCountry>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Nature Reviews Drug Discovery</title>
<idno type="ISSN">1474-1776</idno>
<idno type="eISSN">1474-1784</idno>
<imprint><publisher>Nature Publishing Group</publisher>
<date type="published" when="2005-08">2005-08</date>
<biblScope unit="volume">4</biblScope>
<biblScope unit="issue">8</biblScope>
<biblScope unit="page" from="625">625</biblScope>
<biblScope unit="page" to="626">626</biblScope>
</imprint>
<idno type="ISSN">1474-1776</idno>
</series>
<idno type="istex">C53EDBB7F673A33C12D33AC9B93DBB5D5F1B2FF3</idno>
<idno type="DOI">10.1038/nrd1803</idno>
<idno type="ArticleID">nrd1803</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1474-1776</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="eng">Rasagiline (Azilect; Lundbeck/Teva Pharmaceutical Industries) was given marketing approval by the EMEA for the treatment of Parkinson's disease in February 2005. It is the first in a new generation of selective monoamine oxidase inhibitors, and acts to alleviate the dopaminergic deficit characteristic of the disease.</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
</list>
<tree><noCountry><name sortKey="Kirkpatrick, Peter" sort="Kirkpatrick, Peter" uniqKey="Kirkpatrick P" first="Peter" last="Kirkpatrick">Peter Kirkpatrick</name>
</noCountry>
<country name="Royaume-Uni"><noRegion><name sortKey="Schapira, Anthony" sort="Schapira, Anthony" uniqKey="Schapira A" first="Anthony" last="Schapira">Anthony Schapira</name>
</noRegion>
<name sortKey="Bate, Guy" sort="Bate, Guy" uniqKey="Bate G" first="Guy" last="Bate">Guy Bate</name>
<name sortKey="Schapira, Anthony" sort="Schapira, Anthony" uniqKey="Schapira A" first="Anthony" last="Schapira">Anthony Schapira</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001435 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001435 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:C53EDBB7F673A33C12D33AC9B93DBB5D5F1B2FF3 |texte= Rasagiline }}
This area was generated with Dilib version V0.6.23. |